Ratings DRI Healthcare Trust

Equities

DHT.U

CA23344H1091

Market Closed - Toronto S.E. Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
16.22 ^CAD	-0.86%		-3.80%	+29.97%

04-23	DRI Healthcare Trust Brief: Adds Transaction "Significantly" Reduces Potential Dilution With a Net Reduction of Warrants Equivalent to 8.2% of Units Outstanding	MT
04-23	DRI Healthcare Trust Brief: Says Closed Prior Announced Refinancing of Preferred Securities	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
With an expected P/E ratio at 0 and 181.78 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
DRI HEALTHCARE TRUST	+29.97%	674M	-
ELI LILLY AND COMPANY	+26.47%	661B	C+
NOVO NORDISK A/S	+26.74%	566B	B
JOHNSON & JOHNSON	-6.33%	352B	C+
MERCK & CO., INC.	+19.35%	332B	B-
ABBVIE INC.	+4.23%	283B	C+
ASTRAZENECA PLC	+13.43%	231B	B+
NOVARTIS AG	+4.71%	200B	B-
ROCHE HOLDING AG	-9.53%	195B	A+
AMGEN INC.	-4.04%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes